AbbVie records $4B impairment on Stemcentrx deal

As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Friday it will record a $4 billion impairment charge on its 2016 acquisition of Stemcentrx Inc.